Panel of melanoma mutations opens door to new treatment possibilities

November 15, 2011

Researchers have developed a new genetic screening tool that will aid in the investigation of possible treatments for patients with melanoma and the unique genetic mutations that may accompany the disease, according to data presented at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics, held Nov. 12-16, 2011.

Heinz-Herbert Fiebig, M.D., Ph.D., associate professor of at the University of Freiburg in Germany, presented data from 25 patient-derived melanoma models for which he and his colleagues studied relevant and the effect of new targeted and cytotoxic chemotherapeutic agents.

In this study, Fiebig, who is also the president and CEO of Oncotest GmbH Institute for , and colleagues collected melanoma samples from 80 patients. They were able to grow 38 of them in nude mice from which 25 permanent models were established. Eight different genetic mutations were determined in these models.

"The most prominent mutations were found in the BRAF oncogene; namely, 16 out of 25 tumors were positive for the mutation," said Fiebig.

About 25 percent of melanoma cases had a mutated NRAS gene. PI3Kalpha mutations were rare, and the screening found no mutations of the KRAS gene, which is a common genetic mutation in other forms of cancer.

The researchers then exposed the melanomas bearing specific mutations in vitro in the clonogenic assay to a variety of cancer treatments including traditional cytotoxic chemotherapy drugs, such as cisplatin, paclitaxel or vincristine, and modern that target specific mutations, such as and vemurafenib. They hoped to determine which, if any, of these drugs had an effect on the and whether that effect was related to the presence or lack of a mutation.

The tests indicated that vemurafenib — or PLX-4720 — was most effective in melanoma tumor samples with the V600E mutation in the BRAF gene. This finding echoes those of recent clinical studies in humans. In addition, vincristine was found to only be effective in tumor samples that did not have a mutation in the BRAF gene. "Up until now, we were not able to detect other correlations between chemosensitivity against cytotoxic or targeted agents and other mutations," said Fiebig.

In the melanoma models, vemurafenib was 100 times more active in V600E-mutated melanomas compared with those melanomas with no mutations, Fiebig said. However, in the clinic, the majority of patients developed resistance within one year.

"Our melanoma models will allow researchers to investigate and overcome the possible underlying resistance mechanisms — for example, by combining vemurafenib with other target-specific agents," Fiebig said. "In addition, other new targeted drugs are being studied in a systematic way."

Explore further: Study identifies genes that may help predict response to BRAF inhibitors for advanced melanoma

Related Stories

Study identifies genes that may help predict response to BRAF inhibitors for advanced melanoma

June 1, 2011
Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.